Keeping an eye on $THC after the two-session selloff, while adjusted EBITDA, margins and full-year cash-flow guidance remain strong. The main risk is worsening payer mix and uninsured exposure after a large 2026 run, with recent insider selling adding caution. There may still be details the market is pricing in that I haven't caught yet; this is a watch, not a verdict.
4 views
0 Comments
No comments available.
Join the conversation with 500,000+ other investors 💸
Create an account to get access to everything Blossom has to offer!
📊 Personalized algorithm based on your investing style, experience level and interests
📈 Powerful portfolio and dividend tracking tools
👀 See what top creators and others in the community are investing in